Managing diabetes means a constant stream of small decisions. A new FDA clearance aims to shrink that list. MiniMed announced on November 16 that its first tubeless insulin pump, MiniMed Fit, is now cleared in the U.S. for people with Type 1 and Type 2 diabetes ages 7 and older.
What's in the device
- Up to seven days of wear and a 300-unit insulin capacity
- A waterproof pump controlled through an app on compatible iOS and Android phones
- SmartGuard automation that adjusts insulin and can deliver correction doses every five minutes
- Meal Detection technology that can add insulin when a meal dose is missed or underestimated
The company says that's up to twice the wear time and 50% more insulin capacity than other tubeless options. Those comparisons come from MiniMed's own footnotes, which also note that seven-day wear depends on total daily insulin dose.
Timing and access
At launch, users will be able to choose between two all-in-one sensors: Simplera Sync (up to seven days) or Abbott's Instinct (up to 15 days). A phased U.S. rollout is expected in spring 2027, and the pump will be available through the pharmacy channel, which the company says should make access easier.
The Align takeaway: Health tech is at its best when it removes tasks rather than adding dashboards. Fewer pump changes and more automation could mean fewer interruptions at work, at the gym and while sleeping. As always, this is a company announcement, so talk to your care team about what fits your situation and wait for real-world results.




